Get the Stockscreener App
6.97
3.06%
-0.21
Cybin Inc stock is traded at $6.97, with a volume of 244.50K.
It is down -3.06% in the last 24 hours and up +24.51% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$7.18
Open:
$7.25
24h Volume:
244.50K
Relative Volume:
0.30
Market Cap:
$347.76M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-33.56
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
+4.50%
1M Performance:
+24.51%
6M Performance:
-10.54%
1Y Performance:
-27.58%
1-Day Range:
$6.94
$7.365
1-Week Range:
$6.53
$7.365
52-Week Range:
$4.81
$10.73
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.97 | 358.24M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.85 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.86 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
410.35 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.28 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.67 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Is Cybin Inc. stock gaining market shareQuarterly Market Summary & Daily Stock Trend Reports - Улправда
Is Cybin Inc R7E stock a top hedge fund pickWeekly Market Outlook & Entry and Exit Point Strategies - moha.gov.vn
Why Cybin Inc. stock attracts high net worth investorsGlobal Markets & Stepwise Trade Signal Implementation - Улправда
Is Cybin Inc. (R7E) stock a top hedge fund pickTrade Analysis Summary & Weekly Sector Rotation Insights - Улправда
Can Cybin Inc. (R7E) stock sustain margin levelsMarket Volume Summary & Fast Moving Stock Trade Plans - Улправда
Is Cybin Inc. Common Shares stock a contrarian opportunityJuly 2025 Chart Watch & Low Risk Entry Point Guides - Улправда
Is Cybin Inc a good long term investmentValue Traps to Avoid & Let Our AI Be Your Trading Assistant - earlytimes.in
Cybin to rebrand as Helus Pharma and shift US listing to Nasdaq - MSN
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq - TipRanks
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Yahoo Finance
S P Trends: Is Cybin Inc. stock a good choice for value investorsInsider Buying & Momentum Based Trading Signals - Улправда
Is Cybin Inc. stock attractive after correction2025 Pullback Review & Fast Entry Momentum Trade Alerts - Улправда
What technical signals suggest for Cybin Inc. stockRecession Risk & Fast Exit Strategy with Risk Control - DonanımHaber
Is Cybin Inc. stock attractive for income investorsWeekly Loss Report & Weekly High Return Opportunities - DonanımHaber
What sentiment indicators say about Cybin Inc. stockAnalyst Downgrade & Safe Swing Trade Setups - DonanımHaber
Why retail investors favor Cybin Inc. stockGDP Growth & Weekly High Return Stock Forecasts - DonanımHaber
What dividend safety rating applies to Cybin Inc. Common Shares stockDip Buying & Daily Entry Point Alerts - DonanımHaber
Can Cybin Inc. Common Shares stock deliver strong annual returns2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - Улправда
Why Cybin Inc. stock attracts global investorsJuly 2025 Update & Consistent Return Investment Signals - DonanımHaber
[6-K] CYBIN INC. Current Report (Foreign Issuer) | CYBN SEC FilingForm 6-K - Stock Titan
Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing - Yahoo Finance
How Cybin Inc. Common Shares stock moves in volatile trading sessionsJuly 2025 Rallies & Community Trade Idea Sharing Platform - ulpravda.ru
Signal Recap: Is Cybin Inc. stock a good choice for value investors2025 AllTime Highs & Weekly Setup with High ROI Potential - ulpravda.ru
Why Cybin Inc. stock could be next big winnerJuly 2025 Movers & Reliable Intraday Trade Alerts - Улправда
Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker - simplywall.st
Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Hel - GuruFocus
Cybin to transfer listing from NYSE American to Nasdaq, rebrand - Investing.com
Cybin to transfer U.S. stock exchange listing to Nasdaq - TipRanks
KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Yahoo Finance
Cybin (CYBN) to Transfer Listing to Nasdaq in 2026 - GuruFocus
Cybin to Transfer Listing to Nasdaq From NYSE American - marketscreener.com
Cybin (CYBN) Set to Switch U.S. Listing from NYSE to Nasdaq - GuruFocus
Cybin to move US stock listing to Nasdaq from NYSE American - MSN
Cybin to Shift U.S. Listing to Nasdaq and Rebrand Ticker as HELP - TipRanks
Alerts, brief on Cybin transferring US listing to Nasdaq withdrawn - marketscreener.com
Liquidity Mapping Around (CYBN) Price Events - news.stocktradersdaily.com
Cybin (OTCMKTS:CYBN) Trading 5.5% HigherShould You Buy? - MarketBeat
What drives Cybin Inc stock priceQuarterly Earnings Review & Small Budget Investment Growth - earlytimes.in
Stock Ratings | Guggenheim maintained its "buy" recommendation on Cybin Inc. Common Shares (CYBN) and raised its price target to $48 from $39, representing a potential upside of 378.12%. - Sahm
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet - MSN
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Cybin (OTCMKTS:CLXPF) Shares Up 5.7%Time to Buy? - MarketBeat
Earnings Beat: Why Cybin Inc stock could be next big winnerMarket Risk Summary & Low Volatility Stock Suggestions - BỘ NỘI VỤ
Will Cybin Inc. stock benefit from automationEarnings Beat & High Accuracy Swing Trade Signals - Newser
Will Cybin Inc. (R7E) stock outperform value peersStop Loss & Stepwise Swing Trade Plans - Newser
Is Cybin Inc. (R7E) stock a good hedge against inflation2025 Performance Recap & AI Driven Stock Reports - Newser
Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Can Cybin Inc. (R7E) stock attract ESG investmentsTrade Risk Summary & Reliable Entry Point Trade Alerts - Newser
How geopolitical risks impact Cybin Inc. (R7E) stockJuly 2025 Rallies & Real-Time Volume Analysis - Newser
Cybin price target raised to $48 from $39 at Guggenheim - MSN
Is Cybin Inc. stock overvalued by current metricsJuly 2025 Big Picture & Weekly Market Pulse Updates - Newser
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
3.07%
Cap:
|
Volume (24h):